Figure 4. The synergistic effect of punicalagin and daunorubicin.

NB4, MOLT-4, and peripheral blood mononuclear cells (PBMC) were treated with IC₅₀ of punicalagin with or without daunorubicin for (A) 24 h and (B) 48 h. Cell viability was measured using MTS assay. *p < 0.05 was considered to be a statistically significant difference significant different from the punicalagin or daunorubicin treatment alone.